Company: ANTX
Filing Date: 2025-04-10
Form Type: DEF 14A
Source: 0000950170-25-052852
Chunk: 49

Company: AN2 Therapeutics, Inc.
Filing Date: 2025-04-10
Form: DEF 14A
Chunk 49
---
 expected to exceed the lesser of $120,000 and 1% of our assets and in which a related person has or will have a direct or indirect material interest. The charter of our audit committee will provide that our audit committee shall review and approve in advance any related person transaction.

Our related person transaction policy provides that we are not permitted to enter into any transaction that exceeds the lesser of $120,000 and 1% of our assets and in which any related person has a direct or indirect material interest without the consent of our audit committee. In approving or rejecting any such transaction, our audit committee is to consider the relevant facts and circumstances available and deemed relevant to our audit committee, including whether the transaction is on terms no less favorable than terms generally available to an unaffiliated third party under the same or similar circumstances and the extent of the related person’s interest in the transaction.

<div align='center'>27

PROPOSALS REQUIRING YOUR VOTE

PROPOSAL 1 —Election of Class III Directors</div>

Number of Directors; Board Structure

Our Board currently consists of nine members. Our directors are divided into three classes serving staggered three-year terms. Upon expiration of the term of a class of directors, directors in that class will be eligible to be elected for a new three-year term at the annual meeting of stockholders in the year in which their term expires.

The terms of the Class III directors, Eric Easom, Stephanie Wong, and Joseph Zakrzewski, expire at the Annual Meeting. The Class I directors will serve until our Annual Meeting of Stockholders in 2026. The Class II directors will serve until our Annual Meeting of Stockholders in 2027.

Nominees

As recommended by the nominating and corporate governance committee, the Board has nominated each of Eric Easom, Stephanie Wong, and Joseph Zakrzewski for election as a Class III director. For information concerning the nominees, please see “Directors and Corporate Governance—Board Composition”.

The Class III directors elected at this Annual Meeting will continue in office until our Annual Meeting of Stockholders in 2028 and until the director’s successor has been duly elected and qualified, or until the earlier of the director’s death, resignation or removal. The proxy holders named on the proxy card intend to vote the proxy (if you are a stockholder of record) for the election of Mr. Easom, Ms. Wong and Mr. Zakrzewski, unless you indicate on the proxy card that your